JP2017519723A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519723A5
JP2017519723A5 JP2016565203A JP2016565203A JP2017519723A5 JP 2017519723 A5 JP2017519723 A5 JP 2017519723A5 JP 2016565203 A JP2016565203 A JP 2016565203A JP 2016565203 A JP2016565203 A JP 2016565203A JP 2017519723 A5 JP2017519723 A5 JP 2017519723A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
autoimmune
cells
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519723A (ja
JP6462002B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from KR1020150060182A external-priority patent/KR101705446B1/ko
Priority claimed from PCT/KR2015/004299 external-priority patent/WO2015167243A1/ko
Publication of JP2017519723A publication Critical patent/JP2017519723A/ja
Publication of JP2017519723A5 publication Critical patent/JP2017519723A5/ja
Application granted granted Critical
Publication of JP6462002B2 publication Critical patent/JP6462002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565203A 2014-04-29 2015-04-29 免疫疾患治療効果を有する新規化合物およびその使用 Active JP6462002B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1020140051261 2014-04-29
KR10-2014-0051261 2014-04-29
KR10-2015-0060182 2015-04-29
KR1020150060182A KR101705446B1 (ko) 2014-04-29 2015-04-29 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
PCT/KR2015/004299 WO2015167243A1 (ko) 2014-04-29 2015-04-29 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Publications (3)

Publication Number Publication Date
JP2017519723A JP2017519723A (ja) 2017-07-20
JP2017519723A5 true JP2017519723A5 (https=) 2018-05-17
JP6462002B2 JP6462002B2 (ja) 2019-01-30

Family

ID=54601170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565203A Active JP6462002B2 (ja) 2014-04-29 2015-04-29 免疫疾患治療効果を有する新規化合物およびその使用

Country Status (8)

Country Link
US (2) US20170114008A1 (https=)
EP (1) EP3130582B8 (https=)
JP (1) JP6462002B2 (https=)
KR (1) KR101705446B1 (https=)
CN (2) CN106458869A (https=)
AU (1) AU2015254037B2 (https=)
CA (1) CA2946516C (https=)
ES (1) ES2702337T3 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
KR101949451B1 (ko) 2015-10-13 2019-05-10 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP3679015B1 (en) * 2017-09-05 2024-07-03 1Globe Biomedical Co., Ltd. Novel therapeutics for central nervous system disorders
JP7548669B2 (ja) * 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
KR102147802B1 (ko) * 2018-11-07 2020-08-25 가톨릭대학교 산학협력단 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
CA3121664A1 (en) * 2018-12-04 2020-06-11 The Children's Medical Center Corporation Methods and compositions for treating asthma
KR102316961B1 (ko) * 2020-01-29 2021-10-26 프라비바이오 주식회사 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
CN113907047B (zh) * 2021-12-13 2022-03-11 天津医科大学总医院空港医院 一种自身抗原表位诱导的eam小鼠模型的建立方法
CN115152700B (zh) * 2022-06-28 2023-06-27 广东省人民医院 胶体锰佐剂在制备原发性干燥综合征动物模型中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183956A (en) * 1975-11-05 1980-01-15 William H. Rorer, Inc. Method for treating gastrointestinal spasms, gastrointestinal hyperacidity and hypertensive disorders with amidinoureas
US4060635A (en) * 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
JP5583592B2 (ja) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
JP2013501057A (ja) * 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
KR101136045B1 (ko) * 2009-11-16 2012-04-18 한국화학연구원 Ｎ1-(펜에틸)-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
US9416098B2 (en) 2010-01-06 2016-08-16 Immunomet Therapeutics Inc. Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
JP5894161B2 (ja) 2010-08-25 2016-03-23 ネオファーム カンパニー， リミテッド 新規の複素環化合物及びこれを用いた炎症性疾患治療用組成物
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
KR101432246B1 (ko) * 2011-09-20 2014-08-21 가톨릭대학교 산학협력단 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
CN102698266A (zh) * 2012-05-15 2012-10-03 中国医学科学院北京协和医院 Cd200在制备系统性红斑狼疮治疗药物中的应用
KR101432892B1 (ko) 2012-09-17 2014-08-21 가톨릭대학교 산학협력단 메트포민을 이용한 루프스를 포함하는 면역질환의 예방 또는 치료용 조성물
KR101613371B1 (ko) * 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2017519723A5 (https=)
Halpert et al. The effect of the novel tellurium compound AS101 on autoimmune diseases
Goto et al. Murine NKT cells produce Th17 cytokine interleukin-22
JP2016530265A5 (https=)
Nanjappa et al. Antifungal Tc17 cells are durable and stable, persisting as long-lasting vaccine memory without plasticity towards IFNγ cells
Paroli et al. The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment
Hu et al. Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice
IN2014CN04823A (https=)
WO2018151811A3 (en) Use of tgf alpha for the treatment of diseases and disorders
JP2013523886A5 (https=)
JP2004536105A5 (https=)
JP2013507945A5 (https=)
BRPI0516661A (pt) epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal
Wang et al. Tim-3 signaling pathway as a novel negative mediator in lipopolysaccharide-induced endotoxic shock
Khaled et al. Adult patients with ALL treated with CD62L+ T naïve/memory-enriched T cells expressing a CD19-CAR mediate potent antitumor activity with a low toxicity profile
Volkova et al. A study of the level of circulating cytokines in patients with atopic dermatitis
Moseley et al. Motor imagery for peripheral injury
Wang et al. The Role of Oncogene in Mycobacteria-induced Antophagy in
Petrova et al. The clinical, immunological and laboratory parameters in patients with leptospirosis in St. Petersburg
Pimenova et al. Cytoprotective potential of monoclonal antibodies against Burkholderia pseudomallei
Lee et al. Clinical characteristics and prevalence of toxoplasma infection in human immunodeficiency virus-infected patients in South Korea
Mozgova et al. Cell immunity parameters in K. pneumoniae experimental generalized pyo-inflammatory process
Fujimoto et al. Splenocyte Cytokine Profile in Mouse with Oral Mucosa-sensitization and Oral-tolerization by NiSO4
Cardon et al. Blood stage Plasmodium infection prevents recruitment of T follicular helper cells with high affinity T cell receptors 3412
Rong et al. Inhibting Effects of Cytomegalovirus on Partial Immune Index of Mice Implanted with Methacrylate